KNOCK, KNOCK...NOVO TROLL HERE!

When will Levemir skyrocket past Lantus?

 

Past performance is not indicative of future returns, especially in a world where you have stiff competition. Let's review, Sanofi kicks your butt in the basal market, they have a better product that's easier to use and marketed by a competent organization. You are winning in the RA insulin space but only because Lilly is incompetent. Now with Merck or Sanofi buying Amylin you'll get your butt whooped in the GLP-1 space and you will be downsized fan boy.

Start making friends outside novo, you'll need them this time next year.

 

Lilly incompetent? Lilly is the one who sold BYETTA, that had been proved with the Byedureon launch, besides:

Novo Nordisk Inc. manufactures, markets and/or distributes more than 35 drugs in the U.S.
This company has 5 drugs in the top 200 drugs by U.S. sales (2010).

Eli Lilly and Company manufactures, markets and/or distributes more than 76 drugs in the U.S. This company has 12 drugs in the top 200 drugs by U.S. sales (2010).

 

Hmmmmmmm, you sound a little scared

 

Still waiting to see Levemir "skyrocket" past Lantus.

 

please end this thread and go find out who's buying us, when, and how much.

thanks.

 

I will concede that the Bydureon launch has been less than stellar. Not because it is not a good drug but because our sales leadership team is incompetent. And because stupid loves company so we now have double the stupid with contract sales management teams running around trying to make themselves look important.

Enjoy our easy ride now Novo Troll-the new improved and competently managed Bydureon sales force will be knocking on your door soon enough with a pen delivery that will be similar in size to the one you currently stick up your ass.

 

The only threads that end are the ones about JF. Suspicious

 

So true. That thread got deleted. I guess he is awake and monitoring these boards. Hi Jake!

 

We knew Levemir would never skyrocket past Lantus. It was never planned into brand projections or expected revenue. However, Levemir has gotten almost 20% of the basal market and will do about $600 million this year. The goal is always the same: growth. What's Levemir doing: growing.